viewKazia Therapeutics Ltd

Kazia Therapeutics to begin phase I clinical trial for cancer that has spread to the brain

Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084.

brain scan
Kazia will provide the study drug and a financial grant

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) will investigate the potential use of its drug GDC-0084 in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain, at the Memorial Sloan Kettering Cancer Center (MSK) in New York.

This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer.

Initiation of this study brings to five the total number of ongoing clinical trials with GDC0084, each in different forms of brain cancer.

Kazia chief executive officer Dr James Garner said: “MSK is one of the world’s leading cancer treatment centres, and we are privileged to be supporting them in this state-of-the-art project.

“Many cancers have the potential to spread to the brain, and they become very difficult to treat when they do.

“The work being done at MSK will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy, which remains the current standard of care in most cases.”

READ: Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

MSK will initiate a phase I clinical trial of GDC-0084 in combination with radiotherapy for patients with solid tumour brain metastases (cancer that has spread to the brain) and leptomeningeal metastases that harbours a genetic alteration in the PI3K pathway.

The trial will be led by MSK, with Kazia providing support including study drug and a financial grant and is expected to take about two years to complete.

READ: Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research

Up to 30% of patients with metastatic cancer will develop secondary tumours (metastases) in the brain.

Radiotherapy remains the standard of care, but 30-50% of patients will progress within one year, despite the best available treatment.

In animal models of certain cancers, activation of the PI3K pathway has been shown to contribute to radiotherapy resistance.

GDC0084 is a PI3K inhibitor that can cross the blood-brain barrier, and as such it may be able to reduce the problem of resistance to radiotherapy. This clinical trial has been developed to test that hypothesis.

Personalised medicine

The trial is expected to recruit 18-30 patients, all of whom will have cancer that has spread to the brain.

Patients will be genetically tested for a specific alteration in the PI3K pathway, and only those with a relevant mutation will be enrolled.

This is an example of an approach to clinical research that is sometimes referred to as ‘precision medicine’ or ‘personalised medicine’, in which treatments are carefully targeted to those patients most likely to benefit.

It is expected that the trial will begin recruitment in the second half of calendar 2019.

Quick facts: Kazia Therapeutics Ltd

Price: 0.525 AUD

Market: ASX
Market Cap: $37.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...



Kazia Therapeutics working on moving its flagship Paxalisib drug into...

  Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott after releasing a poster presentation of interim data from the ongoing phase II study of Paxalisib in glioblastoma at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Analysis...

on 06/04/2020

3 min read